Business Description
LadRx Corp
NAICS : 325414
SIC : 2836
ISIN : US2328286081
Description
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 60.71 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 6/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 26.4 | |||||
3-Year EPS without NRI Growth Rate | 31.7 | |||||
3-Year Book Growth Rate | -79.3 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.32 | |||||
9-Day RSI | 35.55 | |||||
14-Day RSI | 38.49 | |||||
6-1 Month Momentum % | 135.77 | |||||
12-1 Month Momentum % | 22.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.18 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 1.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.7 | |||||
Shareholder Yield % | 15.22 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | 399.52 | |||||
ROA % | 64.89 | |||||
ROIC % | -1918.45 | |||||
ROC (Joel Greenblatt) % | -3921.05 | |||||
ROCE % | -859.2 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 0.69 | |||||
PE Ratio without NRI | 0.69 | |||||
Price-to-Owner-Earnings | 0.68 | |||||
PEG Ratio | 0.03 | |||||
PB Ratio | 3.21 | |||||
Price-to-Tangible-Book | 3.2 | |||||
Price-to-Free-Cash-Flow | 0.63 | |||||
Price-to-Operating-Cash-Flow | 0.63 | |||||
EV-to-EBIT | 0.26 | |||||
EV-to-EBITDA | 0.26 | |||||
EV-to-FCF | -0.54 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.03 | |||||
Price-to-Graham-Number | 0.31 | |||||
Price-to-Net-Current-Asset-Value | 3.29 | |||||
Price-to-Net-Cash | 5.89 | |||||
Earnings Yield (Greenblatt) % | 384.62 | |||||
FCF Yield % | 154.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LADX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LadRx Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | 3.27 | ||
Beta | 1.14 | ||
Volatility % | 74.65 | ||
14-Day RSI | 38.49 | ||
14-Day ATR ($) | 0.126326 | ||
20-Day SMA ($) | 2.531705 | ||
12-1 Month Momentum % | 22.47 | ||
52-Week Range ($) | 0.6302 - 4.3 | ||
Shares Outstanding (Mil) | 0.5 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
LadRx Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
LadRx Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
LadRx Corp Frequently Asked Questions
What is LadRx Corp(LADX)'s stock price today?
The current price of LADX is $2.24. The 52 week high of LADX is $4.30 and 52 week low is $0.63.
When is next earnings date of LadRx Corp(LADX)?
The next earnings date of LadRx Corp(LADX) is 2024-08-14 Est..
Does LadRx Corp(LADX) pay dividends? If so, how much?
LadRx Corp(LADX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |